MedTrace Logo

Patient Reported Outcomes in Adults With Severe Eosinophilic Asthma on Benralizumab.

NCT03833141 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 170

Last updated 2024-07-01

No results posted yet for this study

Summary

This study will generate patient reported outcomes (PROs) associated with the use of benralizumab as treatment for severe eosinophilic asthma.

Conditions

  • Severe Eosinophilic Asthma

Interventions

OTHER

Survey Administration

Patient Reported Outcomes (PROs) of health, quality of life, and economic outcomes during routine clinical practice.

Sponsors & Collaborators

Principal Investigators

  • Erika Penz, MD · University of Saskatchewan

Eligibility

Min Age
18 Years
Max Age
130 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-11-12
Primary Completion
2024-05-28
Completion
2024-05-28
FDA Drug
Yes

Countries

  • Canada

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03833141 on ClinicalTrials.gov